Advanced search

Filter By:

Journal Check one or more journals to show results from those journals only.

Choose more journals

Article type Check one or more article types to show results from those article types only.
Subject Check one or more subjects to show results from those subjects only.
Date Choose a date option to show results from those dates only.

Custom date range

Clear all filters
Sort by:
Showing 1–6 of 6 results
Advanced filters: Author: Argyris Dritselis Clear advanced filters

    • Carl Grunfeld
    • Argyris Dritselis
    • Peter Kirkpatrick
    Comments & Opinion
    Nature Reviews Drug Discovery
    Volume: 10, P: 95-96

  • In June 2010, the taxane anticancer drug cabazitaxel (Jevtana; Sanofi–Aventis), in combination with prednisone, was approved by the US Food and Drug Administration (FDA) for the treatment of patients with hormone-refractory metastatic prostate cancer who had been previously treated with a regimen containing the taxane docetaxel.

    • Matthew D. Galsky
    • Argyris Dritselis
    • William K. Oh
    Comments & Opinion
    Nature Reviews Drug Discovery
    Volume: 9, P: 677-678

    • Daniel J. Drucker
    • Argyris Dritselis
    • Peter Kirkpatrick
    Comments & Opinion
    Nature Reviews Drug Discovery
    Volume: 9, P: 267-268

    • Michael J. Keating
    • Argyris Dritselis
    • Peter Kirkpatrick
    Comments & Opinion
    Nature Reviews Drug Discovery
    Volume: 9, P: 101-102

    • Herbert Y. Meltzer
    • Argyris Dritselis
    • Peter Kirkpatrick
    Comments & Opinion
    Nature Reviews Drug Discovery
    Volume: 8, P: 843-844

    • Flavio Vincenti
    • Argyris Dritselis
    • Peter Kirkpatrick
    Comments & Opinion
    Nature Reviews Drug Discovery
    Volume: 10, P: 655-656